Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.
Visco C, Hoeller S, Malik JT, Xu-Monette ZY, Wiggins ML, Liu J, Sanger WG, Liu Z, Chang J, Ranheim EA, Gradowski JF, Serrano S, Wang HY, Liu Q, Dave S, Olsen B, Gascoyne RD, Campo E, Swerdlow SH, Chan WC, Tzankov A, Young KH. Visco C, et al. Among authors: ranheim ea. Am J Surg Pathol. 2011 Feb;35(2):177-89. doi: 10.1097/PAS.0b013e3182049a9c. Am J Surg Pathol. 2011. PMID: 21263238 Free PMC article.
Indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, Wang HY, Cheng JX, Bacon CM, Delabie J, Ranheim E, Kucuk C, Hu X, Weisenburger DD, Jaffe ES, Chan WC. Perry AM, et al. Blood. 2013 Nov 21;122(22):3599-606. doi: 10.1182/blood-2013-07-512830. Epub 2013 Sep 5. Blood. 2013. PMID: 24009234 Free PMC article.
Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.
Chang YI, Damnernsawad A, Allen LK, Yang D, Ranheim EA, Young KH, Zhang J, Kong G, Wang J, Liu Y, Fu HY, Yang CS, Guo J, Song H, Zhang J. Chang YI, et al. Among authors: ranheim ea. Br J Haematol. 2014 Aug;166(3):461-5. doi: 10.1111/bjh.12871. Epub 2014 Apr 3. Br J Haematol. 2014. PMID: 24697267 Free PMC article. No abstract available.
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM. Erbe AK, et al. Among authors: ranheim ea. J Immunother Cancer. 2019 Mar 12;7(1):70. doi: 10.1186/s40425-019-0538-8. J Immunother Cancer. 2019. PMID: 30871628 Free PMC article. Clinical Trial.
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl BS. Evens AM, et al. Among authors: ranheim ea. Clin Cancer Res. 2020 Sep 1;26(17):4468-4477. doi: 10.1158/1078-0432.CCR-20-1345. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532790 Free PMC article. Clinical Trial.
93 results